Lupin is trading higher by around 3% to Rs 734, also its record high on NSE, ahead of fourth quarter (January-March) earnings.
Analyst on an average expected net profit of Rs 306 crore and net sales of Rs 2,385 crore for the quarter ended March 31, 2013 (Q4). The pharmaceutical company had reported net profit of Rs 156 crore and net sales of Rs 1,883 crore during the same quarter of previous year.
“Lupin is expected to register a strong revenue growth of 32.8% mainly on back of strong growth from US and domestic markets. Its EBIDTA is expected to expand by 350bp during the period. On account of which the net profit is to increase by 89.2% in 4QFY2013,” says analyst at Angel Broking.
“We expect an 300bps uptake in EBIDTA margin on the back of Niche product launches and ramp up in market share of exclusive and limited competition products,” says analyst at Antique Stock Broking.
The stock opened at Rs 720 and has seen combined around 515,169 shares changing hands on the counter till early noon deals on NSE and BSE.
Analyst on an average expected net profit of Rs 306 crore and net sales of Rs 2,385 crore for the quarter ended March 31, 2013 (Q4). The pharmaceutical company had reported net profit of Rs 156 crore and net sales of Rs 1,883 crore during the same quarter of previous year.
“Lupin is expected to register a strong revenue growth of 32.8% mainly on back of strong growth from US and domestic markets. Its EBIDTA is expected to expand by 350bp during the period. On account of which the net profit is to increase by 89.2% in 4QFY2013,” says analyst at Angel Broking.
“We expect an 300bps uptake in EBIDTA margin on the back of Niche product launches and ramp up in market share of exclusive and limited competition products,” says analyst at Antique Stock Broking.
The stock opened at Rs 720 and has seen combined around 515,169 shares changing hands on the counter till early noon deals on NSE and BSE.
